144 related articles for article (PubMed ID: 37766492)
1. The in vitro effect of anticoagulant agents on coagulation and fibrinolysis in the presence of emicizumab in the plasmas from patients with haemophilia A.
Onishi T; Harada S; Shimo H; Tashiro Y; Soeda T; Nogami K
Haemophilia; 2023 Nov; 29(6):1529-1538. PubMed ID: 37766492
[TBL] [Abstract][Full Text] [Related]
2. The effects of emicizumab on in vitro coagulation and fibrinolysis parameters in patients with disseminated intravascular coagulation with and without addition of anti-FVIII antibody.
Onishi T; Shimo H; Harada S; Nogami K
Haemophilia; 2024 May; 30(3):836-844. PubMed ID: 38523253
[TBL] [Abstract][Full Text] [Related]
3. Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
Takeyama M; Matsumoto N; Abe H; Harada S; Ogiwara K; Furukawa S; Shimonishi N; Nakajima Y; Yada K; Soeda T; Nogami K
Pediatr Blood Cancer; 2023 Oct; 70(10):e30590. PubMed ID: 37467119
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A.
Nakajima Y; Nogami K; Yada K; Furukawa S; Noguchi-Sasaki M; Hirata M; Shima M
Thromb Haemost; 2020 Jun; 120(6):968-976. PubMed ID: 32384547
[TBL] [Abstract][Full Text] [Related]
5. Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
Yada K; Ogiwara K; Shimonishi N; Nakajima Y; Soeda T; Kitazawa T; Nogami K
Int J Hematol; 2024 Feb; 119(2):109-118. PubMed ID: 38112996
[TBL] [Abstract][Full Text] [Related]
6. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
Nakajima Y; Mizumachi K; Shimonishi N; Furukawa S; Yada K; Ogiwara K; Takeyama M; Shima M; Nogami K
Int J Hematol; 2022 Apr; 115(4):489-498. PubMed ID: 35043383
[TBL] [Abstract][Full Text] [Related]
8. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
9. Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.
Yamada Y; Nakajima Y; Ohara A; Wakita E; Shimizu K; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
Int J Hematol; 2023 Apr; 117(4):607-612. PubMed ID: 36370317
[TBL] [Abstract][Full Text] [Related]
10. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous coagulant potential of emicizumab in neonatal factor VIII-deficient plasma.
Takeyama M; Furukawa S; Onishi T; Noguchi-Sasaki M; Shima M; Nogami K
Pediatr Blood Cancer; 2022 Jul; 69(7):e29731. PubMed ID: 35441786
[TBL] [Abstract][Full Text] [Related]
12. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
13. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
15. Peri-operative hemostatic management of tooth extraction in patients with hemophilia A, with and without inhibitors, receiving emicizumab prophylaxis.
Yagyuu T; Furukawa S; Zaizen M; Yata S; Imada M; Nogami K; Kirita T
Haemophilia; 2023 Jan; 29(1):172-179. PubMed ID: 36163647
[TBL] [Abstract][Full Text] [Related]
16. Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII.
Shimonishi N; Nogami K; Ogiwara K; Matsumoto T; Nakazawa F; Soeda T; Hirata M; Arai N; Shima M
Haemophilia; 2020 May; 26(3):e97-e105. PubMed ID: 32157756
[TBL] [Abstract][Full Text] [Related]
17. Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Kiialainen A; Niggli M; Kempton CL; Castaman G; Chang T; Paz-Priel I; Adamkewicz JI; Levy GG
Haemophilia; 2022 Nov; 28(6):1033-1043. PubMed ID: 35905294
[TBL] [Abstract][Full Text] [Related]
18. Additional Factor X Enhances Emicizumab-Driven Coagulation Function in Patients with Hemophilia A and Hemophilia A Mice.
Shimizu K; Nakajima Y; Takami E; Nakano H; Nogami K
Thromb Haemost; 2024 May; ():. PubMed ID: 38677278
[TBL] [Abstract][Full Text] [Related]
19. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
20. A Pathological Clarification of Sepsis-Associated Disseminated Intravascular Coagulation Based on Comprehensive Coagulation and Fibrinolysis Function.
Onishi T; Nogami K; Ishihara T; Inoue S; Kawaguchi M; Nishio K; Fukushima H; Kobayashi H; Amano I; Nishikubo T; Yamasaki M; Kasahara M; Shima M
Thromb Haemost; 2020 Sep; 120(9):1257-1269. PubMed ID: 32679594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
